These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 34935577)

  • 1. Age and prognosis in patients with pancreatic cancer: a population-based study.
    van Dongen JC; van der Geest LGM; de Meijer VE; van Santvoort HC; de Vos-Geelen J; Besselink MG; Groot Koerkamp B; Wilmink JW; van Eijck CHJ;
    Acta Oncol; 2022 Mar; 61(3):286-293. PubMed ID: 34935577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN).
    McMillan MT; Lewis RS; Drebin JA; Teitelbaum UR; Lee MK; Roses RE; Fraker DL; Vollmer CM
    Cancer; 2016 Feb; 122(4):521-33. PubMed ID: 26587698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
    Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
    Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma.
    Cloyd JM; Crane CH; Koay EJ; Das P; Krishnan S; Prakash L; Snyder RA; Varadhachary GR; Wolff RA; Javle M; Shroff RT; Fogelman D; Overman M; Wang H; Maitra A; Lee JE; Fleming JB; Katz MH
    Cancer; 2016 Sep; 122(17):2671-9. PubMed ID: 27243381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival and Prognostic Factors in Patients With Pancreatic Colloid Carcinoma Compared With Pancreatic Ductal Adenocarcinoma.
    Khalil L; Huang Z; Zakka K; Jiang R; Penley M; Alese OB; Shaib WL; Wu C; Behera M; Reid MD; El-Rayes BF; Akce M
    Pancreas; 2023 Jan; 52(1):e75-e84. PubMed ID: 37378903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different clinical presentations of metachronous pulmonary metastases after resection of pancreatic ductal adenocarcinoma: Retrospective study and review of the literature.
    Lovecek M; Skalicky P; Chudacek J; Szkorupa M; Svebisova H; Lemstrova R; Ehrmann J; Melichar B; Yogeswara T; Klos D; Vrba R; Havlik R; Mohelnikova-Duchonova B
    World J Gastroenterol; 2017 Sep; 23(35):6420-6428. PubMed ID: 29085191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
    Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
    BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic relevance of extracapsular lymph node involvement in pancreatic ductal adenocarcinoma.
    Sergeant G; Ectors N; Fieuws S; Aerts R; Topal B
    Ann Surg Oncol; 2009 Nov; 16(11):3070-9. PubMed ID: 19649555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive factors for long-term survival after surgery for pancreatic ductal adenocarcinoma: Making a case for standardized reporting of the resection margin using certified cancer center data.
    Weyhe D; Obonyo D; Uslar VN; Stricker I; Tannapfel A
    PLoS One; 2021; 16(3):e0248633. PubMed ID: 33735191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of the location of pancreatic ductal adenocarcinoma (head, body, tail) with tumor stage, treatment, and survival: a population-based analysis.
    van Erning FN; Mackay TM; van der Geest LGM; Groot Koerkamp B; van Laarhoven HWM; Bonsing BA; Wilmink JW; van Santvoort HC; de Vos-Geelen J; van Eijck CHJ; Busch OR; Lemmens VE; Besselink MG;
    Acta Oncol; 2018 Dec; 57(12):1655-1662. PubMed ID: 30264642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognosis prediction and comparison between pancreatic signet ring cell carcinoma and pancreatic duct adenocarcinoma: a retrospective observational study.
    Zhou H; Li XX; Huang YP; Wang YX; Zou H; Xiong L; Liu ZT; Wen Y; Zhang ZJ
    Front Endocrinol (Lausanne); 2023; 14():1205594. PubMed ID: 37534212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of Charlson's Age-Comorbidity Index and other risk factors in patients with pancreatic cancer.
    Bagni K; Chen IM; Johansen AZ; Dehlendorff C; Jensen BV; Hansen CP; Preus Hasselby J; Holländer NH; Nissen M; Bjerregaard JK; Pfeiffer P; Yilmaz MK; Rasmussen LS; Nielsen SE; Johansen JS
    Eur J Cancer Care (Engl); 2020 May; 29(3):e13219. PubMed ID: 31908093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of neoadjuvant radiotherapy on survival of non-metastatic pancreatic ductal adenocarcinoma: a SEER database analysis.
    Wang D; Liu C; Zhou Y; Yan T; Li C; Yang Q; Xu Y; Zhao L; Pei Q; Tan F; Güngör C; Li Y
    Radiat Oncol; 2020 May; 15(1):107. PubMed ID: 32404114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival impact based on hepatic artery lymph node status in pancreatic adenocarcinoma: A study of patients receiving modern chemotherapy.
    Perlmutter BC; Hossain MS; Naples R; Tu C; Vilchez V; McMichael J; Tullio K; Simon R; Walsh RM; Augustin T
    J Surg Oncol; 2021 Feb; 123(2):399-406. PubMed ID: 33159317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does Neoadjuvant Chemotherapy Change the Role of Regional Lymphadenectomy in Pancreatic Cancer Survival?
    Macedo FI; Picado O; Hosein PJ; Dudeja V; Franceschi D; Mesquita-Neto JW; Yakoub D; Merchant NB
    Pancreas; 2019 Jul; 48(6):823-831. PubMed ID: 31210664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer.
    Golan T; Sella T; O'Reilly EM; Katz MH; Epelbaum R; Kelsen DP; Borgida A; Maynard H; Kindler H; Friedmen E; Javle M; Gallinger S
    Br J Cancer; 2017 Mar; 116(6):697-702. PubMed ID: 28183138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers.
    Golan T; Kanji ZS; Epelbaum R; Devaud N; Dagan E; Holter S; Aderka D; Paluch-Shimon S; Kaufman B; Gershoni-Baruch R; Hedley D; Moore MJ; Friedman E; Gallinger S
    Br J Cancer; 2014 Sep; 111(6):1132-8. PubMed ID: 25072261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between Pancreatic Fistula and Long-term Survival in the Era of Neoadjuvant Chemotherapy.
    Hank T; Sandini M; Ferrone CR; Rodrigues C; Weniger M; Qadan M; Warshaw AL; Lillemoe KD; Fernández-Del Castillo C
    JAMA Surg; 2019 Oct; 154(10):943-951. PubMed ID: 31411659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perioperative blood transfusions and survival in resected pancreatic adenocarcinoma patients given multimodality therapy.
    Newhook TE; Prakash LR; Soliz J; Hancher-Hodges S; Speer BB; Wilks JA; Bruno ML; Dewhurst WL; Arvide EM; Maxwell JE; Ikoma N; Kim MP; Lee JE; Katz MHG; Tzeng CD
    J Surg Oncol; 2021 Dec; 124(8):1381-1389. PubMed ID: 34398988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The significance of relative dose intensity in adjuvant chemotherapy of pancreatic ductal adenocarcinoma-including the analysis of clinicopathological factors influencing relative dose intensity.
    Yabusaki N; Fujii T; Yamada S; Murotani K; Sugimoto H; Kanda M; Nakayama G; Koike M; Fujiwara M; Kodera Y
    Medicine (Baltimore); 2016 Jul; 95(29):e4282. PubMed ID: 27442667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.